Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
NCT05970510 is registered in ClinicalTrials.gov with Luye Pharma Group Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ⅲ Study to Evaluate the Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Participants With Generalized Anxiety Disorder.
- Lead sponsor
- Luye Pharma Group Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 4, 2023
- Completion date
- July 31, 2025
- Enrollment
- 555 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.